Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders? {"summary":"","positive":[],"negative":[],"faq":[]}

#ESQ #ULY #BRNS Are NSA, ULY, ESQ, BRNS Obtaining Fair Deals for their Shareholders?

www.stocktitan.net/news/ESQ/are-nsa-uly-esq...

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments Barinthus Bio (NASDAQ: BRNS) reported 2025 results and announced a proposed all-stock combination with Clywedog, expected to close in Q2 2026 and trade as CLYD. Cash was $71.9 million at December 31, 2025, with an estimated runway through 2027.VTP-1000 Phase 1 multiple ascending dose data are expected in H2 2026; single ascending dose data showed tolerability and pharmacodynamic T cell recognition.

#BRNS Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

www.stocktitan.net/news/BRNS/barinthus-bio-...

Trade Alerts, Monday January 12, 2026 – Crystal Equity Research

Small-cap stocks with improving money flow, Mon Jan 12th - #OKYO #HGBL #WLFC #SIFY #PLTS #MBRX #LYRA #IVA #EVTV #CPSH #BRNS #ADTN #EEX #CLW - More: crystalequityresearch.com/trade-alerts... - #smallcap

Barinthus reports positive Phase 1 results for VTP-1000 in celiac disease Barinthus Biotherapeutics (BRNS) announced that its experimental immunotherapy VTP-1000 was well tolerated in the single-ascending-dose (SAD) part of the Phase

Barinthus #BRNS reports positive Phase 1 results for VTP-1000 in celiac disease
prismmarketview.com/barinthus-re...

#BRNS Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

www.stocktitan.net/news/BRNS/barinthus-bio-...

Halper Sadeh LLC Urges Shareholders to Explore Their Rights with Upcoming Mergers Halper Sadeh LLC encourages shareholders of BRNS, FITB, ADVM, and HBAN to discuss their legal rights regarding recent mergers and acquisitions, which may have potential violations.

Halper Sadeh LLC Urges Shareholders to Explore Their Rights with Upcoming Mergers #USA #New_York #Halper_Sadeh_LLC #FITB #BRNS

Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments S ingle ascending dose data readout for VTP-1000 expected before the end of 2 025 Enrollment advancing in multiple ascending dose part of the AVALON trial; data expected in the second half of 2026 Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) to strengthen and diversify the

#BRNS Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments

www.stocktitan.net/news/BRNS/barinthus-bio-...

ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics SAN DIEGO, Oct. 24, 2025/ PRNewswire/-- ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, computational, and clinical pharmacology support to Clywedog Therapeutics as the company enters into a definitive merger agreement with Barinthus Therapeutics. The combined entity will operate...

#BRNS ChemDiv Continues R&D Services Support for Clywedog Therapeutics Following Merger with Barinthus Therapeutics

www.stocktitan.net/news/BRNS/chem-div-conti...

Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being studied for the prevention/reversal of Type 1 and Type 2 Diabetes and the treatment of Celiac Disease. Four key value-driving milestones are

#BRNS Barinthus Biotherapeutics to Combine with Clywedog Therapeutics to Target Metabolic and Autoimmune Diseases

www.stocktitan.net/news/BRNS/barinthus-biot...

Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments Barinthus Bio (NASDAQ: BRNS) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $87.8 million in cash, projecting runway into 2027. Key developments include the initiation of the final cohort in the Phase 1 AVALON trial's Single Ascending Dose (SAD) portion for VTP-1000 in celiac disease, with data expected in early Q4 2025.Q2 financial highlights show R&D expenses of $8.0 million (down from $8.3M in Q1) and G&A expenses of $15.4 million (up from $12.6M in Q1). The company reported a net loss of $21.1 million ($0.52 per share). The VTP-850 prostate cancer trial completed with encouraging immunogenicity data, and the company is actively seeking partners for multiple programs.

#BRNS Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

www.stocktitan.net/news/BRNS/barinthus-bio-...

Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025; Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and

#BRNS Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

www.stocktitan.net/news/BRNS/barinthus-bio-...

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments Barinthus Bio (NASDAQ: BRNS) has reported its full year 2024 financial results and corporate updates, highlighting its strategic transformation into an immunology and inflammatory disease-focused company. The company's lead asset, VTP-1000, a potentially curative immunotherapy for celiac disease, is progressing with first data expected in Q3 2025.Key financial highlights include:Cash position of $112.4 million as of December 31, 2024Revenue of $15.0 million in 2024, up from $0.8 million in 2023Net loss of $61.1 million ($1.55 per share)Research and development expenses of $42.2 millionThe company's SNAP-TI platform shows promise in promoting antigen-specific immune tolerance. In chronic hepatitis B trials, VTP-300 demonstrated encouraging results with eight participants achieving undetectable HBsAg levels. The company's cash runway is expected to extend into 2027.

#BRNS Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

www.stocktitan.net/news/BRNS/barinthus-bio-...

Barinthus Bio Pivots to Celiac Disease Drug, Cuts 65% of Workforce in Major Strategic Shift Barinthus Bio refocuses on immunology with VTP-1000 for celiac disease, halts hepatitis B program, and restructures to extend $112M cash runway through 2027.

#BRNS Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

www.stocktitan.net/news/BRNS/barinthus-bio-...

#BRNS Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

www.stocktitan.net/news/BRNS/barinthus-bio-...

#BRNS Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

www.stocktitan.net/news/BRNS/barinthus-bio-...

Un mix entre l'énergie de Foals, les sonorités de Wu Lyf, un poil d'Arcade Fire. Ce concert c'était du lourd. #NuitsSoniques #BRNS